GSK PLC – Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
RNS Number : 7605R GSK PLC 24 August 2026 Issued: 24 August 2026, London UK Jemperli (dostarlimab) accepted for
RNS Number : 7605R GSK PLC 24 August 2026 Issued: 24 August 2026, London UK Jemperli (dostarlimab) accepted for
RNS Number : 8441R GSK PLC 24 August 2026 24th August 2026, London UK Hibsago (bepirovirsen) approved in
RNS Number : 9778M GSK PLC 20 July 2026 Issued: 20 July 2026, London UK European Medicines Agency
RNS Number : 9745L GSK PLC 13 July 2026 Issued: 13 July 2026, London UK Jemperli (dostarlimab) achieves sustained
RNS Number : 0138B GSK PLC 20 April 2026 Issued: 20 April 2026, London UK Blenrep (belantamab mafodotin)